Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.56 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | XIAP | P98170 | 9/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.45 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9973474 | 0.98 | CASP1 (0.54) | CASP1FKBP1AKMT2AL3MBTL1XIAP | |
| SCHEMBL9973468 | 0.89 | CASP1 (0.48) | CASP1FKBP1AKMT2AL3MBTL1XIAP | |
| SCHEMBL31384849 | 0.89 | CASP1 (0.48) | CASP1FKBP1AKMT2AL3MBTL1XIAP | |
| SCHEMBL9973466 | 0.89 | CASP1 (0.48) | CASP1FKBP1AKMT2AL3MBTL1XIAP | |
| SCHEMBL9973467 | 0.88 | CASP1 (0.49) | CASP1FKBP1AKMT2AL3MBTL1XIAP | |
| SCHEMBL31384817 | 0.88 | CASP1 (0.49) | CASP1FKBP1AKMT2AL3MBTL1XIAP | |
| SCHEMBL9973469 | 0.88 | CASP1 (0.49) | CASP1FKBP1AKMT2AL3MBTL1XIAP | |
| SCHEMBL1299624 | 0.88 | CASP1 (0.47) | CASP1FKBP1AKMT2AL3MBTL1XIAP | |
| SCHEMBL1299626 | 0.88 | CASP1 (0.47) | CASP1FKBP1AKMT2AL3MBTL1XIAP | |
| SCHEMBL1299623 | 0.88 | CASP1 (0.47) | CASP1FKBP1AKMT2AL3MBTL1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4463459-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118804917-A | STAT modulators and uses thereof | 瑞克鲁迪克斯制药股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | CASP1 2275/4885FKBP1A 1107/4885KMT2A 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.